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Two major isoforms of the Runx2 gene are expressed by alterna-
tive promoter usage: Runx2 type I (Runx2-I) is derived from the
proximal promoter (P2), and Runx2 type II (Runx2-II) is produced
by the distal promoter (P1). Our previous results indicate that Dlx5
mediates BMP-2-induced Runx2 expression and osteoblast differ-
entiation (Lee, M.-H., Kim, Y-J., Kim, H-J., Park, H-D., Kang, A-R.,
Kyung, H.-M., Sung, J-H.,Wozney, J.M., Kim, H-J., and Ryoo, H-M.
(2003) J. Biol. Chem. 278, 34387–34394).However, little is knownof
the molecular mechanisms by which Dlx5 up-regulates Runx2
expression in BMP-2 signaling. Here, Runx2-II expression was
found to be specifically stimulated by BMP-2 treatment or by Dlx5
overexpression. In addition, BMP-2,Dlx5, andRunx2-IIwere found
to be expressed in osteogenic fronts and parietal bones of the devel-
oping cranial vault and Runx2-I and Msx2 in the sutural mesen-
chyme. Furthermore, Runx2 P1 promoter activity was strongly
stimulated by Dlx5 overexpression, whereas Runx2 P2 promoter
activitywasnot.Runx2P1promoter deletion analysis indicated that
the Dlx5-specific response is due to sequences between 756 and
342 bp of the P1 promoter, where three Dlx5-response elements
are located. Dlx5 responsiveness to these elements was confirmed
by gelmobility shift assay and site-directedmutagenesis.Moreover,
Msx2 specifically suppressed the Runx2 P1 promoter, and the
responsible region overlaps with that recognized by Dlx5. In sum-
mary, Dlx5 specifically transactivates the Runx2 P1 promoter, and
its action on the P1 promoter is antagonized by Msx2.
The Runt-related transcription factor Runx2 plays an essential role in
osteoblast differentiation and bone mineralization (1, 2). Two major
isoforms are expressed from themouseRunx2 locus, and these isoforms
are generated by different promoter usage. Runx2 type I (Runx2-I),2
referred to as the Cbfa1/p56 isoform or PEBP2A, is a 513-amino acid
protein that starts with the amino acid sequence MRIPV (3) and is
derived from the proximal P2 promoter of the gene (4). More recently,
upstream exons of theRunx2 gene that potentially encode theN termini
of Runx2 isoforms expressed in osteoblasts have been identified (5, 6).
These upstream exons contain a 5-untranslated region and encode the
N-terminal 19 amino acids of Runx2 type II (Runx2-II; also referred to as
Cbfa1/p57 and OSF2), which starts with the sequence MASNSL (7).
This isoform is expressed from the P1 or “bone-related” upstream pro-
moter (8), and its expression is predominant in osteoblasts (9). The
alternative promoter usage strongly implies that the expression pattern
of each isoform differs temporally and/or spatially. Indeed, they exhibit
distinct expression patterns during bone development (10, 11). Thus, it
is natural to assume that these two promoters differently respond to
different extracellular signals or their downstream transcription factors
because these promoters have distinct transcription factor-binding
sites.
Runx2 plays a central role in the BMP-2-induced trans-differentia-
tion of C2C12 cells at an early restriction point by diverting them from
the myogenic pathway to the osteogenic pathway (12, 13). We found
that the homeobox gene Dlx5 is an upstream target of BMP-2 signaling
and that it plays a pivotal role in stimulating the downstream osteogenic
master transcription factor Runx2. In turn, Runx2 acts simultaneously
or sequentially to induce the expression of bone-specific genes that
represent BMP-2-induced osteogenic trans-differentiation. In addition,
it has also been suggested that Dlx5 is a critical target of the inhibitory
action of transforming growth factor-1 (TGF-1) on BMP-2-induced
osteoblast trans-differentiation (14).
Several lines of in vivo evidence indicate that theDlx andMsx families
of homeodomain proteins include regulatory factors that preferentially
support skeletal tissue differentiation. Among them, Dlx5 is a bone-
inducing transcription factor that is expressed in the later stages of
osteoblast differentiation (15). Forced expression of Dlx5 in cultured
cells leads to osteocalcin expression and a fully mineralized matrix (14,
16, 17). These results strongly suggest that Dlx5 plays important roles in
the development ofmineralized tissues. Another homeodomain protein
that plays critical roles in bone formation and osteoblast differentiation
(Msx2) is also induced by bone morphogenetic proteins (BMPs) (18).
Several in vitro studies have shown that Msx2 negatively regulates the
transcription of osteoblast-specific genes such as osteocalcin (15, 19).
This was further supported by findings that the Dlx5 andMsx2 proteins
bind the promoters of osteoblast markers and appear to have opposing
transcriptional properties because Msx2 functions as a transcriptional
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repressor (20–22), whereas Dlx5 is an activator of osteoblast marker
gene expression (15, 23–25).
Dlx5 is the key mediator of BMP-induced Runx2 expression (14), but
little is known about how it regulates Runx2 expression in response to
BMP-2 signaling. Therefore, the first aim of this study was to assess
which promoter responds to BMP signaling because Runx2 has two
major isoforms whose expression is regulated by alternative promoters.
In addition, as Dlx5 acts downstream of BMP-2, we undertook to define
cis-acting elements in the BMP-2-responsive Runx2 promoter that
interact with Dlx5. Finally, as Msx2 is thought to inhibit the Dlx5-in-
duced expression of osteoblast marker genes (20, 21), we also explored
the relationship of these two transcription factors with respect to the
Runx2 promoter. Here, we demonstrate that Dlx5 up-regulates Runx2
(more specifically, Runx2-II) expression and that the effect of Dlx5 on
the Runx2 P1 promoter is antagonized by Msx2.
EXPERIMENTAL PROCEDURES
Materials—Bioactive recombinant human BMP-2 was from Wyeth
Pharmaceuticals (Cambridge, MA). Recombinant human TGF-1 was
purchased fromR&DSystems (Minneapolis,MN). Dulbecco’smodified
Eagle’s medium, -minimal essential medium, fetal bovine serum, and
Lipofectamine PLUSTM reagent were from Invitrogen. Tissue culture
plasticware was from Corning (Corning, NY); the Megaprime DNA
labeling system was from Amersham Biosciences; DNA midi-prep kits
were from Qiagen Inc.; and ExpressHyb hybridization solution was
from Clontech. The Zeta-Probe blotting membrane was from Bio-Rad,
and the Dual-Luciferase reporter assay kit, Taq polymerase, Pfu polym-
erase, dNTPmixture, pGL3-Basic vector, and TNT coupled reticulocyte
lysate system were from Promega Corp. Anti-FLAG monoclonal anti-
body M2, HEPES, Nonidet P-40, EDTA, dithiothreitol, phenylmethyl-
sulfonyl fluoride, glycerol, and poly(dI-dC) were purchased from Sigma.
Cell Culture and Northern Blot Analysis—Mouse myogenic C2C12
cells, osteoblast-likeMC3T3-E1 cells, and the rat osteosarcoma cell line
ROS17/2.8 were maintained as described previously (12). C2C12 cells
stably transfected withDlx5, antisense (AS)Dlx5 (Dlx5-AS), Msx2, and
antisenseMsx2 (Msx2-AS) constructs were established andmaintained
as described previously (14). The Runx2/ calvarial cell line H1-127-
21-2 was maintained as described previously (13). Chinese hamster
ovary cells was maintained in -minimal essential medium in the pres-
ence of 10% fetal bovine serum. C2C12 cells were plated at a density of
1  106 cells/100-mm culture dish. To examine the effects of BMP-2 or
TGF-1 on cell differentiation, the cells were cultured for the indicated
periods with or without the indicated factors in medium with 5% fetal
bovine serum. All cells were harvested with phosphate-buffered saline
by scraping with a rubber policeman at 4 °C. Total RNA was extracted
from the cells, and Northern blot analysis for Runx2 was performed as
described previously (14).
Reverse Transcription-PCR and Quantitative Real-time PCR—Con-
ventional reverse transcription-PCR for murine Runx2 was performed
with the primers described previously (26). Quantitative real-time PCR
was carried out using SYBR Green fluorescence dye on a LightCycler
machine (Roche Applied Science, Mannheim, Germany) as described
previously (27). PCR primers for mouse Runx2 (forward, 5-CCA-
GAATGATGGTGTTGACG-3; and reverse, 5-GGTTGCAAGAT-
CATGACTAGGG-3) and mouse glyceraldehyde-3-phosphate dehy-
drogenase (26) were synthesized by TaKaRa Korea (Seoul, Korea). All
samples were run in triplicate, and the relative levels of Runx2
mRNA were normalized to those of glyceraldehyde-3-phosphate
dehydrogenase.
DNAConstructs—The construction of theDlx5,Dlx5-AS,Msx2, and
Msx2-AS expression vectors and the establishment of each stable cell
line have been described previously (14, 25). The mouse Runx2 P1 pro-
moter (2782 to112 bp) and theRunx2P2 promoter (4056 to246
bp) were generated based onGenBankTM accession numbers AF155360
(from 1784 to 4677 bp) and AF155361 (from 1 to 4303 bp), respectively.
The Runx2 P1 and Runx2 P2 promoter deletion constructs were gener-
ated by serial deletion from the 5-end of the promoter with mung bean
nuclease, and the fragments were ligated into the KpnI/BglII and SmaI
sites, respectively, of the pGL3-Basic vector. The Runx2 P1 promoter
deletion constructs P1342 (342 to 112 bp), P1756 (756 to
112 bp), P11664 (1664 to 112 bp), and P12782 (2782 to
112 bp) were cloned into the pGL3-Basic vector, as were theRunx2 P2
promoter deletion constructs P2857 (857 to 246 bp), P21843
(1843 to 246 bp), P22648 (2648 to 246 bp), and P24056
(4056 to 246 bp). The Runx2 P1 promoter deletion constructs
P1458 (458 to 112 bp; containing the Dlx5 D3-binding site) and
P1610 (610 to 112 bp; containing the Dlx5 D2/D3-binding sites)
were constructed using P1756 as a template. The forward primers
(bearing a KpnI restriction site for the P1458 and P1610 constructs)
and the reverse primer (bearing a StuI restriction site) are listed in
TABLE ONE. Each PCR product was digested with KpnI and StuI and
subcloned into the KpnI/StuI-digested Runx2 P1756 vector. Myc-
tagged Dlx5 and FLAG-taggedMsx2 were subcloned into pcDNA3.1.
Site-directed Mutagenesis of Dlx5-binding Sites—To produce con-
structs that bear mutations of each binding site alone, two sites, or all
three sites in the three putative homeodomain-response elements
(HDREs) of the Runx2 P1756 construct, a site-directed mutagenic
two-step PCR strategy was followed. For the first set of PCRs, three
mutant primers designatedMTD1 (661 to616 bp),MTD2 (591 to
537 bp), and MTD3 (399 to 352 bp) (TABLE ONE) were used as
TABLE ONE
Primer sequences for construction of Runx2 promoter deletion mutants and site-directed mutagenesis
The lowercase letters correspond to restriction enzyme sites for KpnI (forward primers) or StuI (reverse primer). The lowercase italic boldface letters designate
the substitution of nucleotide for site-directed mutagenesis. The sequence location was calculated from the transcription start site of the Runx2 P1 promoter.
Name Oligonucleotide sequence Sequence location
bp
P1610 5-GCggtaccGCCACACACTCAGTTGAGAC-3 (forward) 610 to 591
P1458 5-CAggtaccTGCTCTCCAGAGGCTTAACC-3 (forward) 458 to 439
Reverse 5-CTTGTGGTAaggcctTCCTG-3 331 to 350
MTD1 5-GATACAATCCCAAGATGCGAgcgggTGCAAAGCAGCACTGTTGCTC-3 (forward) 661 to 616
MTD2 5-CAATTTTGCTCACTTTTCCATAGACAccgtcgccAAGGAAAGGGAGGAGGGGTAG-3 (forward) 591 to 537
MTD3 5-CAAATCCTCATGAGTCACAAAAgcggcAAAGCTATAACCTTCTGAATG-3 (forward) 399 to 352
GL2 5-CTTTATGTTTTTGGCGTCTTCCA-3 (reverse)
RV3 5-CTAGCAAAATAGGCTGTCCC-3 (forward)
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the forward primers, and the GL2 primer (Promega Corp.) was used as
the reverse primer to create Runx2-MTD1, Runx2-MTD2, and Runx2-
MTD3, respectively, using the Runx2 P1756 construct as a template.
In the second round of PCR, the RV3 primer (Promega Corp.) was used
as the forward primer, and PCR products from the first roundwere used
as the reverse primers with P1756 as a template. The cycling param-
eters for PCRwere as follows: 94 °C for 60 s, 48 °C for 1min (first round)
or 44 °C for 1 min (second round), and 72 °C for 2 min for 35 cycles,
followed by 72 °C for 10 min. PCR products with mutated binding sites
were digested with KpnI/PstI, and the resulting 868-bp fragments were
ligated to pGL3-Basic. Derivatives with two or three mutated sites were
constructed using combinations of each mutant construct described
above. All constructs were confirmed by sequencing (Macrogen, Seoul).
In Situ Hybridization—Probe preparation (BMP-2, Dlx5, Msx2,
Runx2-I, and Runx2-II), tissue preparation, and in situ hybridization
procedures were as described previously (10). Calvariae of ICR mice
(embryonic day 16)were prepared as described previously (28). Sections
were stained with hematoxylin and eosin to assess the developing cal-
varia. The 240-bpmurine BMP-2 fragment in pGEM3 (Promega Corp.)
was digested with HindIII or EcoRI. The 800-bp rat Dlx5 fragment in
pCR2 (Invitrogen) was digested with BamHI or XbaI. The 850-bp
murineMsx2 fragment in pSP72 (Invitrogen) was digested with HindIII
or BglII. In all three cases, antisense and sense riboprobes were pro-
duced by T7 and SP6 RNA polymerases, respectively. Runx2-I- and
Runx2-II-specific riboprobe preparation and in situ hybridization were
as described previously (10, 28).
Transfection and Luciferase Assay—C2C12, ROS17/2.8, and
Runx2/ cells were plated in 6-well plates at a density of 1  105
cells/well. After overnight culture, cells were transfected with Lipo-
fectamine PLUSTM according to the manufacturer’s instructions. Each
transfection assay was performed with 0.5 g of the Dlx5 or Msx2
expression vector or pcDNA3 and 0.5 g of the Runx2 promoter-lucif-
erase reporter vector. All plasmid DNA was prepared using a DNA
midi-prep kit. Three hours after transfection, themediumwas changed,
and the cells were cultured for the indicated periods. The cells were then
harvested, and luciferase activity was determined with a Dual-Lucif-
erase reporter assay kit. The results presented are representative data
from at least three independent experiments with triplicate samples.
Electrophoretic Mobility Shift Assay (EMSA)—The oligonucleotide
sequences of three putative homeodomain-binding sites between 342
and756 bp from the transcription start site of the Runx2 P1 promoter
were synthesized (Takara Bio Inc., Shiga, Japan) (see Fig. 4D). The
mutantD3oligonucleotideswere synthesized by substituting theATTA
sequence with the underlined sequences in Fig. 4D. These double-
stranded DNA probes were end-labeled with [-32P]dCTP using Kle-
now enzyme. The Dlx5 and Msx2 proteins were produced by in vitro
transcription and translation using the TNT coupled reticulocyte lysate
system. Nuclear extracts from C2C12 or Chinese hamster ovary cells
that were transiently transfected with Dlx5 for 24 h were prepared as
described previously (29). TheDlx5 orMsx2 proteinwas incubatedwith
labeled double-stranded DNA probes in the absence or presence of a
50-, 100-, or 500-foldmolar excess of unlabeled competitor for 20min at
room temperature. For the supershift assay, Dlx5 orMsx2 was preincu-
bated with anti-Dlx5 rabbit polyclonal antibody (14) or anti-FLAG
monoclonal antibodyM2, respectively, for 20min at room temperature
before incubationwith the labeled probe. Protein-DNAcomplexeswere
separated at 4 °C on a 6% polyacrylamide gel containing 0.5 Tris
borate/EDTA.
Chromatin Immunoprecipitation Assays—Chromatin immunopre-
cipitation assays were performed as described in detail previously (30,
31). C2C12 cells were transiently transfected with the Myc-Dlx5 or
FLAG-Msx2 construct for 24 h. PCR primer pairs were generated to
detect DNA segments located between nucleotides 715 and 431 of
themouseRunx2 distal promoter (nucleotide1 is themRNAcap site):
forward, 5-AACAGAAGGAAGCAGCCACC; and reverse, 5-CCA-
CACTCCTGTAAGGTTAAGC.
RESULTS
Runx2-II Is Specifically Stimulated by BMP-2 and Dlx5—Our previ-
ous study showed that both BMP-2 and TGF-1 stimulate Runx2
expression in C2C12 cells (12). In this study, we found that BMP-2
treatment stimulated the expression of Runx2-II (5.4 kb) (Fig. 1A,
arrow) and Runx2-I (6.0 kb) (arrowhead) transcripts, whereas TGF-1
treatment stimulated mainly Runx2-I expression. Runx2-II expression
was more strongly stimulated by BMP-2 treatment compared with
Runx2-I expression. In addition, overexpression of Dlx5, which medi-
ates Runx2 expression in response to BMP-2 signaling (14), also specif-
ically stimulated Runx2-II transcription (Fig. 1B, lanes 5 and 6). More-
over, in cells stably transfected with Dlx5-AS (14), the antisense
intervention of Dlx5 specifically blocked the BMP-2-stimulated expres-
sion of Runx2-II, but not Runx2-I (Fig. 1B, lanes 1–4).
We previously demonstrated that these two Runx2 isoforms are dif-
ferentially expressed during intramembranous bone formation in
mouse cranial and axial bone development (10, 11). As Runx2-II expres-
sion was specifically induced by BMP-2 treatment or by overexpression
of its immediate downstream target geneDlx5, we examined the expres-
sion of BMP-2, Dlx5, and Runx2 in the developing mouse calvaria. The
pattern of Dlx5 expression matched those of BMP-2 and Runx2-II (Fig.
2, A–C). All three transcripts were strongly expressed in osteogenic
fronts and parietal bones, but not in poorly differentiated sutural mes-
enchymal cells, whereas Runx2-I and Msx2 were strongly expressed in
the latter cells (Fig. 2, E and F).
Dlx5 Specifically Enhances Runx2 P1 Promoter Activity—Because
expression of the twomajor isoforms of Runx2 is differentially regulated
by two different promoters and because both BMP-2 treatment and
Dlx5 overexpression are more closely associated with Runx2-II, the P1
promoter product, we analyzed the responsiveness of the Runx2 P1 and
P2 promoters to Dlx5 overexpression. For this purpose, we prepared a
series of 5-deletion constructs as illustrated in Fig. 3A. The basal pro-
moter activity of P1 promoter deletion constructs was notably stronger
than that of P2 promoter deletion constructs (Fig. 3B).
FIGURE 1. Runx2-II is specifically stimulated by BMP-2. A, MC3T3-E1 cells were
untreated (control (C)) or treated with BMP-2 (B; 300 ng/ml) or TGF-1 (T; 5 ng/ml) for
72 h. B, mock-transfected C2C12 cells or C2C12 cells stably transfected with Dlx5 or
Dlx5-AS (14) were untreated or treated with 300 ng/ml of BMP for 72 h. The Dlx5-AS-
expressing cell lines did not express Dlx5 protein in the treatment with BMP-2 in our
previous study (14). Total RNA was analyzed by Northern blot hybridization with a full-
length Runx2 cDNA probe with glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
as a loading control. The two major Runx2 transcripts, Runx2-I (6.0 kb; arrowheads) and
Runx2-II (5.4 kb; arrows), and 18 S and 28 S rRNAs are designated.
Dlx5 Specifically Regulates Runx2-II Expression




























P1 promoter deletion analysis indicated a strong increase in reporter
activity between P1342 and P1756 in both non-osteogenic (C2C12)
and osteogenic (ROS17/2.8) cells. Interestingly, the stimulatory activity
of Dlx5 disappeared for longer constructs in these cells (P11664 and
P12782) (Fig. 3, B and C). In contrast, the stimulatory effect of Dlx5
was determined in P1756 and was still observed for longer constructs
(P11664 and P12782) in Runx2/ cells (Fig. 3C). Taken together,
these results suggest that theDlx5-response element in the P1 promoter
is located between 756 and 342 bp from the Runx2-II transcription
start site.
IdentificationofDlx5-responseElements intheRunx2P1Promoter—Insilico
analysis of the Runx2 P1 promoter indicated that it contains three putative
HDREs between nucleotides 756 and 342, which have the core binding
sequenceATTA.WedesignatedthesesitesasD1,D2,andD3(Fig.4D).TheD2
site includes two successive homeodomain-binding core sequences, and the
D3site is locatedclosely to theSmad1-andAP1-bindingconsensussequences.
As Runx2-II expression is stimulated by Dlx5, we determined whether Dlx5
binds to theseputativeHDREsbygelmobility shift assays. For this experiment,
D1, D2, and D3 oligonucleotides bearing the core sequence plus surrounding
nucleotides (designatedWT in Fig. 4D) were synthesized, labeled, and used in
EMSAswith in vitro translatedDlx5protein.The radiolabeledD1,D2, andD3
probes clearly formed a binding complexwith theDlx5 protein (Fig. 4A, lanes
2). Furthermore, binding of Dlx5 to each labeled probe was diminished in the
presenceofamolarexcessofunlabeledD1(Fig.4A, lanes3–5),D2(lanes6–8),
FIGURE 2. Expression patterns of BMP-2, Dlx5,
Msx2, and Runx2 isoforms in the developing
mouse sagittal suture. Serial coronal tissue sec-
tions of embryonic day 16.5 mouse calvariae were
hybridized with 35S-UTP-labeled riboprobes
BMP-2 (A), Dlx5 (B), Runx2-II (C), Msx2 (E), Runx2-I (F).
The intensity of the red dots indicates the expres-
sion level of each mRNA. Hematoxylin and eosin
staining (H&E) of the tissue section is shown in D. D,
dura mater; P, parietal bone; OF, osteogenic fronts;
S, skin; SM, sutural mesenchyme.
FIGURE 3. The Runx2 P1 promoter is specifically activated by Dlx5 overexpression. Serial deletion constructs of the Runx2 P1 and P2 promoters are illustrated in A. C2C12 cells (B),
ROS17/2.8 cells (C), and Runx2/ cells (clone H1-127-21-2) (D) were transfected with Runx2 P1 promoter-reporter constructs (P1342, P1756, P11664, and P12782) or with
Runx2 P2 promoter-reporter constructs (P2857, P21843, P22648, and P24056) together with a Dlx5 expression vector or a mock vector. The luciferase (Luc) activity was
measured and normalized to the protein concentration in the cell lysates.
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affinity among these sites. Bands corresponding to each protein-DNA probe
complexwere supershiftedwhen anti-Dlx5 antibodywas introduced (Fig. 4A,
lanes 12).
This EMSA analysis was performed with D3 site mutants (designated
D3MT in Fig. 4D). The Dlx5 binding affinity almost disappeared in the
mutant D3 probe (Fig. 4B, lane 3). Furthermore, the binding between
the labeled wild-type D3 probe and Dlx5 was not competed by a 50- or
100-fold molar excess of unlabeled mutant D3 probe (Fig. 4B, lanes 4
and 5). The supershift (asterisk) and weakened original shift (arrow) by
anti-Dlx5 antibody confirmed the specificity (Fig. 4B, lane 6). Dlx5 bind-
ing to the sequence was further confirmed using nuclear extracts from
C2C12 and Chinese hamster ovary cells that were transiently trans-
fected with Dlx5 (Fig. 4C, lanes 2–5 and 8–11).
To understand the functional consequence of Dlx5 binding to each
HDRE for Runx2 P1 promoter activity, we performed site-directed
mutagenesis on each binding site alone (D1, D2, or D3 site mutant) or
on two (D1/D2, D2/D3, or D1/D3 site mutants) or three sites in the
Runx2 P1756 construct. Constructs with single or double binding site
mutations were not sufficient to block P1 promoter activity to 50% of
FIGURE 4. Three putative HDREs in the Runx2 P1 promoter specifically bind to Dlx5. A, 32P-labeled D1 (left panel), D2 (center panel), and D3 (right panel) probes was incubated with
in vitro translated Dlx5. Lanes 1, free probe; lanes 2–11, Dlx5 protein incubated with the labeled Dl, D2, or D3 probe alone (lanes 2) or in the presence of a 50-, 100-, or 500-fold molar
excess of unlabeled D1 oligonucleotides (lanes 3–5, respectively), unlabeled D2 oligonucleotides (lanes 6 – 8, respectively), or unlabeled D3 oligonucleotides (lanes 9 –11, respectively);
lanes 12, Dlx5 binding confirmed by a supershift assay with anti-Dlx5 antibody. The arrowheads indicate binding of Dlx5 to each probe, and the asterisks indicate a supershift by
anti-Dlx5 antibody. B, 32P-labeled D3 oligonucleotides corresponding to the wild-type (WT) and mutant (MT) D3 probes were incubated with in vitro translated Dlx5 protein. The
probe was incubated with the rabbit reticulocyte lysates that were used for in vitro transcription and translation (lane 1). The Dlx5 protein was incubated with the labeled wild-type
D3 probe (lane 2), whose binding to Dlx5 was competed by a 50- or 100-fold molar excess of unlabeled mutant competitor (MTComp) oligonucleotides (lanes 4 and 5, respectively).
The Dlx5 protein was incubated with the labeled mutant D3 probe (lane 3). Dlx5 binding was confirmed by a supershift assay (lane 6). C, C2C12 and Chinese hamster ovary (CHO) cells
were transiently transfected with Dlx5 for 1 day. The nuclear extracts were prepared and incubated with oligonucleotides corresponding to the wild-type D3 probe. Lanes 1 and 6, free
probe; lanes 2–5 and 8 –11, Dlx5-transfected nuclear extracts, lane 7, mock vector-transfected nuclear extract. Binding of the D3 probe to Dlx5 was subjected to competition (Comp)
from a 50-fold (lanes 3 and 9) or 100-fold (lanes 4 and 10) molar excess of unlabeled wild-type oligonucleotides. The mobility shift caused by Dlx5 binding was confirmed by a
supershift assay (lane 11). The arrowheads indicate binding of Dlx5 to the probe, and the asterisk indicates a supershift by anti-Dlx5 antibody. D, the Runx2 P1 promoter construct
bearing three putative HDREs in the region between 756 and 112 bp was subjected to site-directed mutagenesis of all three sites to substitute the ATTA sequence with the
designated sequences (boxed). ROS17/2.8 cells were cotransfected the wild-type Runx2 P1756 construct (WT bars) or the triple mutant reporter vector (MT bars) together with the
Dlx5 expression vector or empty vector. Luc, luciferase.
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thewild-type level (data not shown).However, themutations of all three
binding sites finally blocked the response to Dlx5 in ROS17/2.8 cells,
from 3.4-fold (Fig. 4D,WT bars) to 1.5-fold (MT bars). These obser-
vations indicate that all three HDREs are required for Dlx5 binding and
that they are responsible for the stimulation of Runx2-II expression by
Dlx5.
Msx2 Suppresses Runx2-II Expression by Binding to the Runx2 P1
Promoter—The BMP-induced transcription of Runx2 was suppressed
by stable transfection of Msx2 and increased by stable transfection of
Msx2-AS (Fig. 5A). The level of Runx2 expression was only 30% of the
control level inMsx2-overexpressing cells and 2.3-fold higher inMsx2-
AS-overexpressing cells as determined by real-time PCR analysis (day 3
sample). The real-time PCR products after 30 cycles are shown in the
day 3 sample.
In addition, when ROS17/2.8 cells were cotransfected with Runx2
promoter-reporter constructs together with the Msx2 expression vec-
tor, Msx2 strongly suppressed the reporter activity of the Runx2
P11664, P1610, and P1458 constructs, but not of the Runx2
P1342 construct (Fig. 5B). P1 promoter activitywas suppressed to 25%
of the control level, but the P2 promoter was not inhibited by Msx2
overexpression.
Based on these results, we speculate that Msx2 also recognizes the
response elements in the P1 promoter that are occupied byDlx5. To test
the binding activity of Msx2 and these elements, we performed EMSA.
The labeled D3 probe effectively bound toMsx2 (Fig. 5C, lanes 2, 5, and
8). Furthermore, binding of Msx2 to the labeled D3 probe was reduced
in the presence of a 50- or 100-fold molar excess of unlabeled D1 (Fig.
5C, lanes 3 and 4), D2 (lanes 6 and 7), or D3 (lanes 9 and 10) probe,
suggesting that their binding affinity might be equivalent. The super-
shift confirms that the binding complex hasMsx2 (Fig. 5C, lane 11).We
also found that mutation of all three binding sites in the Runx2 P1756
construct almost completely abrogated the suppressive ability of Msx2
overexpression in ROS17/2.8 cells (Fig. 5D), whereas mutation of each
binding site alone or two sites was not sufficient to allow P1 promoter
activity to be suppressed to 50% of the wild-type level (data not
shown).
Dlx5 andMsx2 Reciprocally Antagonize EachOther’s Action by Com-
peting Common Response Elements—To examine the antagonistic
mechanism between Dlx5 and Msx2 on the Runx2 P1 promoter, we
performed EMSA in which the labeled D3 probe was incubated with a
constant amount ofMsx2 (Fig. 6A, arrowhead) and increasing amounts
of Dlx5 (asterisk). When more Dlx5 protein was present, binding of
Msx2 to the D3 probe was decreased. The in vivo binding/recruitment
of Dlx5 and Msx2 to the Runx2 P1 promoter (Dl, D2, and D3 sites) was
shown by chromatin immunoprecipitation (Fig. 6B).
FIGURE 5. Msx2 suppresses Runx2-II expression by binding to the Runx2 P1 promoter. A, mock-transfected C2C12 cells or C2C12 cells stably transfected with Msx2 or Msx2-AS (25)
were treated with 100 ng/ml BMP-2 for 1 (1d) or 3 (3d) days after reaching visual confluence, and Runx2 expression was determined by conventional reverse transcription-PCR or
quantitative real-time PCR (3 days). The relative levels of Runx2 mRNA were normalized to those of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). B, ROS17/2.8 cells were
transfected with Runx2 P1 or P2 promoter deletion constructs along with the Msx2 expression vector or empty vector. Luc, luciferase. C, the 32P-labeled D3 probe was incubated with
in vitro translated FLAG-tagged Msx2. The free probe is shown in lane 1. The shift by FLAG-tagged Msx2 protein (lanes 2, 5, and 8) was competed by a 50- or 100-fold molar excess of
unlabeled D1 (lanes 3 and 4, respectively), D2 (lanes 6 and 7, respectively), or D3 (lanes 9 and 10, respectively) oligonucleotides. The mobility shift caused by Msx2 binding was
confirmed by a supershift assay with anti-FLAG antibody (lane 11). The arrowhead indicates a shift complex, and the asterisk indicates a supershift complex. D, ROS17/2.8 cells were
cotransfected with the wild-type Runx2 P1756 construct (WT bars) or the triple mutant (MT bars) together with the Msx2 expression vector or empty vector.
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The antagonistic action of Dlx5 and Msx2 on Runx2 expression was
investigated. C2C12 and ROS17/2.8 cells were transfected with the
Runx2 P1756 promoter-reporter construct together with the Dlx5
and/orMsx2 expression vector. The stimulatory effect of Dlx5 and the
inhibitory effect of Msx2 were reciprocally compromised by the other’s
action (Fig. 6C). Taken together, these results indicate thatMsx2 antag-
onizes the stimulatory effect of Dlx5 on theRunx2 P1 promoter and that
all three Dlx5-response elements in the Runx2 P1 promoter show func-
tional consequences of Msx2 antagonism in the regulation of Runx2-II
expression.
DISCUSSION
BMP Signaling Specifically Stimulates the Expression of Runx2-II—The
overall genomic organization of RUNX2, including the presence of dual pro-
moters, is remarkably conserved in othermembers of this family of transcrip-
tion factors, including RUNX1 and RUNX3 (32, 33). According to previous
reports, the dual promoters are quite distantly separated, by7 kb inRUNX1
and 35 kb in RUNX3. A data base analysis of human chromosome 6p12 indi-
cated that the twoRUNX2promotersare themostdistantly separated,by93
kb. Similarly, the twoRunx2promoters are also80 kb apart onmouse chro-
mosome17.Wepreviously indicatedthat thesealternativepromotersproduce
two Runx2 isoforms, which are differentially expressed in intramembranous
andendochondralbone-formingprocesses (10,11).Morerecently,weshowed
thatDlx5 isan indispensablemediatorofBMP-2-inducedRunx2expression in
the osteogenic trans-differentiation ofC2C12myogenic cells (14).
In addition to these prior findings, in this study, we have shown that
expression of Runx2-II, a bone-specific isoform, commonly co-localizes
with that of BMP-2 and Dlx5 duringmouse calvarial bone development
(Fig. 2). These observations suggest that the Runx2 P1 promoter is a
specific target of BMP-2 signaling and Dlx5 action. As two major tran-
scripts of Runx2 are similar in size (5.4 and 6.0 kb), it is not easy to
demonstrate their differential expression by Northern blot analysis. In
this study, we used lower concentration of agarose gel (1%) and longer
running times to separate these highermolecularmass transcriptsmore
clearly. Our results indicate that Runx2-II expression is specifically reg-
ulated by BMP-2 treatment. Consistently, Runx2-II expression was
clearly stimulated by Dlx5 overexpression and inhibited by Dlx5-AS
treatment. As far as we have observed, the two Runx2 isoforms are not
functionally different with respect to osteoblast differentiation in trans-
genicmice (34). Nonetheless, it is evident that theRunx2 P1 promoter is
more specifically regulated by Dlx5 compared with the Runx2 P2 pro-
moter. Thus, the differential regulation of the two promoters by certain
signaling pathwaysmay explain the distinct temporal/spatial expression
patterns of the two isoforms during bone development (10, 11).
Runx2 Isoforms: Functional Difference Versus Differential Transcrip-
tional Regulation—BMP-2 is very important for the normal bone-re-
modeling process. It is produced and secreted by osteoblasts as a
propeptide and is accumulated in the bone matrix. When bone resorp-
tion occurs, enzymes secreted fromosteoclasts degrade the bonematrix
and release the matrix-incorporated BMP-2 in a short mature form,
which in turn stimulates new bone formation in the area.
The selective Runx2-II deficiency in mice by targeted deletion of the
Runx2 P1 promoter and exon 1 demonstrates that Runx2-I is sufficient
for early skeletogenesis and intramembranous bone formation, whereas
Runx2-II is necessary for endochondral bone formation and turnover in
mature bones (35, 36). These findings highly correlate with the fact that
Runx2 3-kb P1 promoter-driven LacZ expression continues throughout
chondrogenesis and is restricted to the axial skeleton (37).
In this study, we first identified three Dlx5-response elements in the
Runx2 P1 promoter. In contrast, the Runx2 P2 promoter did not
respond to Dlx5, a crucial transcription factor for BMP-2 action. Thus,
it can be assumed that there was a great disturbance in BMP-2-induced
endochondral bone formation as well as BMP-2-mediated normal bone
remodeling in the Runx2-II-deleted mice. Meanwhile, Runx2-I expres-
FIGURE 6. Dlx5 and Msx2 reciprocally antago-
nize each other’s action by competing common
response elements. A, binding of the radiola-
beled D3 probe to the Msx2 protein was com-
peted by the Dlx5 protein. Each protein was trans-
lated in vitro. The free probe is shown in lane 1. A
major binding complex with FLAG-Msx2 (lane 2)
was competed by a 100-fold molar excess of unla-
beled D3 competitor (Comp; lane 3) or anti-FLAG
antibody (lane 4). Lanes 5–7, the binding complex
with Msx2 (arrowhead) was gradually completed
by the addition of increasing amounts of Dlx5
(asterisk). The binding complex with Msx2 (arrow-
head) was gradually competed by the addition of
increasing amounts of Dlx5 (asterisk) B, chromatin
immunoprecipitation assays were performed with
C2C12 cells transiently transfected with Myc-Dlx5
or FLAG-Msx2. Anti-Myc or anti-FLAG antibody
mediated the precipitation of chromatin frag-
ments PCR-amplified with Runx2 P1 primers. C and
D, C2C12 and ROS17/2.8 cells, respectively, were
transiently cotransfected with the Runx2 P1756
construct together with the Dlx5 and/or Msx2
expression vector.
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sion stimulated by other factors than the BMP-2 signal (for example,
fibroblast growth factor or TGF) is sufficient for embryonic skeletogen-
esis and intramembranous bone formation.
Contribution of Dlx5 andMsx2 to Bone Development—The Dlx5 and
Msx2 proteins appear to act in an antagonistic manner during osteo-
blast differentiation. Dlx5 is expressed during later stages, coincident
with the expression of osteocalcin (15), and it has been found to activate
the promoters of osteocalcin and other bone-specific marker genes (14,
16, 20), clearly indicating that it stimulates osteoblast differentiation. In
contrast, the role played by Msx2 is negative. It has been suggested that
Msx2 stimulates cell proliferation and suppresses osteogenic differenti-
ation because its expression precedes osteocalcin expression and pre-
vents the terminal differentiation of osteoblasts (38).
Several models can be proposed to explain the antagonistic action of
Dlx5 and Msx2. First, the two proteins may interact to form a complex
that is functionally inactive because DNA-binding homeodomains are
obscured (39). This idea is illustrated by their interaction with the
Runx2 protein: Runx2 andMsx2 interact to form a complex, andMsx2-
bound Runx2 is transcriptionally inactive. The addition of Dlx5 to the
Runx2-Msx2 complex releases Runx2 because Dlx5 sequesters the
Msx2 protein, thus restoring the transcriptional activity of Runx2 (21).
Second, the homeodomains of the Dlx5 and Msx2 proteins may com-
pete for binding to their common response elements in bone-specific
marker genes such as osteocalcin (15, 40) and alkaline phosphatase (25).
Our present results strongly suggest another possibility: Dlx5 andMsx2
reciprocally regulate osteoblast differentiation through their antagonis-
tic regulation of the expression of Runx2-II, themajor Runx2 isoform in
bone tissue. Furthermore, based on their expression patterns in calvarial
bone development (28) and in in vitro osteoblast differentiation (41), it is
also possible that they regulate each other at the transcriptional level (i.e.
Msx2 suppresses Dlx5 expression and vice versa).
Two recently reported studies proposed an alternative action ofMsx2
in osteoblast differentiation. One is that BMP-2-induced Msx2 expres-
sion in vascular smooth muscle cells stimulates their osteogenic differ-
entiation, which is consequently related to the development of an ath-
erosclerotic lesion (42). The other is that overexpression of Msx2 in
pluripotentmesenchymal progenitor cells suppresses adipogenic differ-
entiation and stimulates osteogenic differentiation (43). These results
appear incompatible with our present data, but correspond well with
other in vivo results that a gain-of-function mutation in Msx2 (P148H)
that increases its affinity for DNA (44) results in Boston-type craniosyn-
ostosis, which is characterized by premature cranial suture closure (45).
However, osteoblast differentiation was determined 7 days after viral
infection ofMsx2, in contrast to our study, in which we assayed osteo-
genesis 24 h after transfection. Thus, it is unclear whether the stimula-
tory activity ofMsx2 that was shown previously was due to direct action
on bone marker genes or to an accumulation of secondary effects of
Msx2 overexpression. In contrast, our results clearly indicate that the
Msx2 action on Runx2-II regulation is direct. Nevertheless, this double-
edged function of Msx2 might also be explained by temporal consider-
ations. For example, Msx2 promotes the proliferation of osteoprogeni-
tor cells in the early stage of cell differentiation and prevents terminal
osteoblast differentiation by acting as a repressor. Supporting the pro-
liferation of osteoprogenitor cells increases the population size of these
cells; because these cells will go on to differentiate into osteoblasts,
Msx2 can be seen to stimulate osteoblast differentiation.
In conclusion, we have shown that Runx2-II expression is specifically
regulated by BMP-2 signaling and that this regulation ismediated by the
Dlx5 protein and response elements between 756 and 342 bp of the
Runx2 P1 promoter, where three putative homeodomain-binding sites
are located. All three response elements contribute to Dlx5 binding and
stimulation of promoter activity. Similar to what was found for the
alkaline phosphatase promoter (25), the action of Dlx5 on the Runx2 P1
promoter is antagonized byMsx2. Thus, for the BMP-2-induced osteo-
genic trans-differentiation of C2C12 cells, immediately induced Msx2
suppresses Runx2-II expression and permits an increase in a committed
cell population. The BMP-2-induced osteogenic differentiation may
continue until Msx2 is down-regulated and Dlx5 is up-regulated. Col-
lectively, Msx2, Dlx5, and Runx2 may define a cascade of factors that
contribute to initial lineage determination, proliferation, and differen-
tiation in BMP-2-induced osteoblast differentiation, and Dlx5 appears
to be a component of the combinatorial mechanism that controls the
formation and differentiation of skeletal tissues.
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